U.S.-based PleoPharma announced yesterday that the FDA has granted it a fast-track designation for PP-01, a new ...

Speaking this week at BIO CEO, the heads of Septerna, Upstream Bio and Actuate Therapeutics shared lessons from going public ...

Researchers at the University of Toronto see a future where a single injection under the eyelid could replace months of daily eye drops to treat glaucoma, a leading cause of blindness.

Novartis' strong drug pipeline and financials support an 11% annual return by 2027. Learn why NVS stock offers 33% return ...

It’s possible that GLP-1s may be useful for a range of substance use disorders, including opioid use disorder and nicotine ...

Aardvark’s lead candidate ARD-101 is being investigated in a Phase III study for hyperphagia in Prader-Willi syndrome.

Recursion is advancing REC-617, a promising reversible, non-covalent CDK7 inhibitor, showing potential in treating advanced solid tumors with positive interim phase 1 data. Read more here.

Hundreds of millions of dollars of life-saving medical supplies are stranded in warehouses and on ships around the world due ...

Healthcare isn't the hottest sector these days. While the S&P 500 has soared nearly 21% over the last 12 months, healthcare ...

Veru Inc (VERU) advances its biopharmaceutical pipeline with promising clinical results while navigating financial hurdles ...

Total operating expenses for the fourth quarter of 2024 were $287 million, including non-cash stock-based compensation of $40 ...

A virus originally found in animals, mpox -- which causes the disease of the same name -- is now circulating in humans. Since 2022, it has been the cause of major epidemics spreading outside endemic ...